| Description | Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity. |
| In vivo | Mitoquidone (MTQ) 在多种实验性实体瘤模型中显示出良好活性，但对于如P388小鼠白血病等标准预筛选模型活性较弱。共有27名患者接受MTQ治疗，给药方式为每21天一次4小时静脉注射（150-600 mg/m^2），每周一次（每周200 mg/m^2），或每28天5天连续给药（每天60-180 mg/m^2）。两名患有淋巴瘤的患者出现了B症状的暂时缓解。观察到线性药动学特性，末次血浆半衰期为2.9 +/- 2.1小时（n = 18次给药）。分布容积为3.4 +/- 2.6 l/kg，血浆清除率为629 +/- 469 ml/min per m^2。[1] |
| molecular weight | 299.32 |
| Molecular formula | C20H13NO2 |
| CAS | 91753-07-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: < 1 mg/mL (insoluble） |
| References | 1. Speth PA, et al. Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol. 1988 ; 21(4):343-346. |